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Thromboembolic stroke from the left atrial appendage (LAA) is the most feared complication in patients with
atrial fibrillation (AF). The cornerstone for the management of chronic non-valvular AF is stroke reduction
with oral anticoagulation (OAC). However, poor compliance, maintaining a narrow therapeutic window, and
major side effects such as bleeding have severely limited their use, which creates a therapeutic dilemma.
As much as 20% of AF patients are not receiving OAC due to contraindications and less than half of AF
patients are not on OAC due to reluctance of the prescribing physician and/or patient non-compliance.
Fortunately, over the past decade, there have been great interests in providing an alternative strategy
unbeknownst to the practicing internist. The introduction of percutaneous approaches for LAA occlusion has
added a different dimension to the management of chronic AF in patients with OAC intolerance. Occlusion
devices such as the Amplatzer Cardiac Plug and WATCHMAN device are currently being investigated for
stroke prophylaxis. More recently, the LARIAT device may provide an alternative means for potential stroke
prophylaxis without the need for short-term post-procedural OAC. We aim to review the current literature
and bring attention to an alternative strategy for high-risk AF patients intolerant to OAC.
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A
trial fibrillation (AF) accounts for 1520% of all
strokes in the United States (1). In one popula-
tion-based study, it is estimated that 2.3 million
US adults have AF and by 2050 it is projected to increase
to 5.6 million (1). Other studies have estimated an even
larger prevalence of greater than 10 million, highlighting
its significance (2). Thromboembolic stroke from the left
atrial appendage (LAA) is the most feared complication.
The cornerstone for the management of chronic non-
valvular AF is stroke reduction with oral anticoagula-
tion (OAC). However poor compliance, maintaining a
narrow therapeutic window, and major side effects such
as bleeding have severely limited their use, which creates a
therapeutic dilemma (3). As much as 20% of AF patients
are not receiving OAC due to contraindications and less
than half of AF patients are on OAC due to either phy-
sician reluctance or patient non-compliance (4, 5). Over
the past decade, there has been great interest in provid-
ing an alternative strategy to anticoagulation. The intro-
duction of percutaneous approaches for LAA occlusion
has added a different dimension to the management of
chronic AF in patients with OAC intolerance. Several
implantation devices such as the percutaneous left
atrial appendage transcatheter occlusion (PLAATO†),
Amplatzer† Cardiac Plug (ACP), and the WATCH-
MAN† LAA system have been investigated for stroke
prophylaxis (6). In addition to these occlusion devices,
a novel pre-tied suture device called the LARIAT† has
also been described in the literature (7).
Methods
Literature search strategy
An extensive electronic English language literature search
was done using PubMed and Medline, to identify peer-
reviewed original and reviewarticles or abstracts using the
key words ‘WATCHMAN’, ‘AMPLAZTER’, ‘LARIAT’,
and ‘PLAATO’ from 1992 through 2013. In this review,
we provide data on these devices. A total of 207 papers
wereidentified andofthese papers9 arediscussed. Studies
involving non-catheter based procedures, non-prospective,
and non-randomized clinical trials were excluded. The
mechanism, efficacy, and limitations when available are
discussed.
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It is widely accepted that thrombus formation in the
LAA is the result of stagnant blood flow (8). In patients
with non-valvular AF, transesophageal echocardio-
graphy (TEE) studies have shown the LAA as the site
of more than 90% of thrombi formation and the most
likely source of cardioembolic stroke (8). The American
College of Cardiology and the American Heart Associa-
tion have recommended surgical amputation of the LAA
during mitral valve surgery to reduce stroke risk (9).
Surgical approaches have been attempted to obliterate the
LAA; however, it is often restricted to concomitant
surgical procedures such as mitral valve surgery. More-
over, surgical ligation during mitral valve surgery is often
incomplete (up to 36%), leaving a potential nidus for
thrombus formation and risk for an embolic event (10).
The limitations of surgery and intolerance to OAC have
prompted the need for other approaches.
Percutaneous devices for left atrial appendage
occlusion
Percutaneous left atrial appendage transcatheter
occlusion
Percutaneous left atrial appendage transcatheter occlu-
sion (PLAATO†, ev3 Inc., Plymouth, MN) was the
first catheter-based approach for LAA occlusion (Fig. 1)
(11). Multiple observational studies were carried out to
evaluate the safety and efficacy of the PLAATO system.
Despite these multiple studies showing PLAATO’s pro-
mising results (see Table 1), there were no plans to
proceed with a phase II or III trial due to lack of funding
and it was discontinued in 2005 (1215).
Amplatzer cardiac plug (ACP)
The ACP was introduced in 2002 by Meier et al., who
adapted the concept of the Amplatzer septal occluder
used for atrial septal defects (ASD) and patent foramen
ovale (PFO) closure to exclude the LAA (Fig. 2) (16).
In a retrospective single center study with a 10-year
follow-up, Nietlispach et al. evaluated 152 patients who
received ACP device implantation (17). The safety end-
points were pericardial effusions, device embolization,
procedure-related stroke and major bleeds (17). The
efficacy endpoints were cardiovascular and unexplained
deaths, neurologic events including ischemic and hemor-
rhagic stroke or transient ischemic attacks, and systemic
embolism (17). In the overall population, no patients
reached the efficacy endpoints within 6 months of im-
plantation (17). The major concern was device thrombus
and residual leak into the LAA limiting the discontinua-
tion of OAC for at least 3 months (17). Although it
was concluded that closure using the ACP device is
an alternative to OAC, the benefits, long-term outcomes,
and duration of OAC post-implantation still remain
unclear (17, 18).
The device is currently unavailable in the United States,
though ongoing clinical trials involving a prospective
multicenter 2:1 randomization to a device or warfarin are
in progress.
WATCHMAN device
The WATCHMAN LAA system is the best-studied
occlusion device (Fig. 3). The largest conducted clinical
trial compared the WATCHMAN device to warfarin in
the WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients with AF (PROTECT AF)
trial. The primary endpoints of efficacy included stroke,
death, and systemic embolization (20). Safety endpoints
included bleeding and procedure-related complications
(20). Successful implantation was achieved in 88% (408/
463) of patients (20). 86% of the patients were able
to discontinue warfarin at 45-day follow-up and 92% of
the patients were able to discontinue warfarin at 6 months
(20). The primary efficacy event rate was 3.0 per 100
patient-years (95% credible interval [CrI] 1.94.5) with
the WATCHMAN device and 4.9 per 100 patient-years
(95% CrI: 2.87.1) in the warfarin group (20). For
successfully implanted patients, the primary efficacy
event rate was lower at 1.9 per 100 patient-years (95%
CrI: 1.03.2) (20). The 21 patients who were assigned
to the intervention group died secondary to events
unrelated to device closure (20). The cumulative mortality
rate at 1 year for the device was 3.0% (95% CI: 1.34.6)
compared to the warfarin group at 3.1% (95% CI:
0.85.4) (20). At 2 years, the morality rate was 5.9%
(95% CI: 2.88.9) and 9.1% (95% CI: 4.214.1) with
the device compared to the warfarin group, respectively
(20). Primary safety events occurred at a higher rate Fig. 1. PLAATO Device (26).
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Study Year Study Type Device
Subjects
(N) Follow-up Stroke Outcome
Procedure-
Related Death Complications (No. of Persons) Efficacy
Ostermayer
et al. (12)
2005 Prospective PLAATO 111 10 months Stroke/TIA 2.2% (versus
estimated 6.3%)
6 Implant failure (3),
hemopericardium (5)
65% reduction in stroke risk
Block et al.
(13)
2009 Prospective PLAATO 64 5 years Stroke 3.8% (versus
estimated 6.6%)
1 Death and cardiac tamponade (1),
major stroke (5), minor stroke (3)
42% reduction in stroke risk
Meier et al.
(16)
2003 Prospective ACP 16 Average 4
months
(range 112)
0% stroke/TIA 0 Device embolization (1) Stable implantation with
average of 4 months
Nietlispach
et al. (17)
2013 Prospective ACP
(dedicated
and non-
dedicated)
152 Mean 32
months
(range
1120)
2 TIA and 1 minor stroke
(non-dedicated device)
and 0 for ACP device
0 Short-term outcome (B 6 months):
Neurologic events (2), Cardiac
tamponade (4), Device embolization
(7), non-cardiac death (1)
Intermediate-term outcome
(  6 months): Cardiovascular
death (5), non-cardiac death (7),
unexplained death (3), neurological
events (2), systemic embolization
(1), major bleed (4)
Improved short-term
outcome with dedicated
ACP device, safety events
occur approximately 7% of
patients, intermediate-term
outcome ( 6 months)
excellent, device thrombus
(16%)
Sick et al.
(19)
2007 Prospective WATCHMAN 75 2 years 0% stroke/TIA 1 Implant failure (2), device failure,
embolization, or pericardial effusion
(6), TIA’s (2)
Warfarin could be stopped
at 6 months in 97.1% of
patients
PROTECT
AF (21)
2009 Randomized
controlled trial
WATCHMAN 707 18 months 2.3%; 6 years 3%; 4 years Adverse events higher among
controls
 99% probability of
non-inferior to warfarin
ASAP (22) 2012 Prospective WATCHMAN 150 3 and 12
months
(mean of
14.298.7
months)
75% reduction in
ischemic stroke with
aspirin (7.1% reduction)
vs. aspirin and clopidogrel
(5% reduction).
Unknown Total stroke (4), systemic embolism
(1), device-related thrombus by
TEE (6)
Watchman without warfarin
post-device implantation is
safe and effective.
Bartus et al.
(24)
2011 Feasibility LARIAT 13 60 days 0% stroke/TIA 0 Hemopericardium (1) Technically feasible in
humans
Bartus et al.
(25)
2012 Prospective LARIAT 89 12 months 2 Non-embolic stroke 2 Right ventricular puncture (1),
laceration of epigastric vessels (1),
hemopericardium (1), pericarditis (2)
98% complete LAA closure
at 1 year
ACP, Amplatzer Cardiac Plug; PLAATO, percutaneous left atrial appendage transcatheter occlusion; TIA, transient ischemic attack.
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)in the device group (RR 1.69, 95% CrI: 1.013.19) than
in the control group early on, though primary safety
event rates in successfully implanted patients no longer
receiving warfarin post-implantation were lower (RR
0.35, 95% CrI: 0.150.80) than the control group (20).
Most of the complications (55% of the patients) occurred
on the day of the procedure, which was attributed to
perioperative complications and operator experience
(20). Complications included serious pericardial effu-
sions requiring pericardiocentesis (4.8%), major bleeding
(3.5%), procedure-related ischemic stroke (1.1%), device
embolization (0.6%), and hemorrhagic strokes (0.2%)
(20). It was concluded that although the WATCHMAN
device met non-inferiority to warfarin therapy, there was
a higher rate of adverse safety events due to peri-
procedural complications (20).
A subsequent analysis of the PROTECT AF trial by
Reddy et al. addressed safety by investigating the
influence of operator experience with the WATCHMAN
device (21). The continued access registry study was a
prospective clinical trial that compared the outcomes in
patients who received the WATCHMAN device (Con-
tinued Access Protocol [CAP]) with the PROTECT
AF group (21). The primary safety outcomes included
bleeding and procedure related events such as pericardial
effusion, stroke, and device embolization (21). The
authors showed a significant decline in the rate of
procedure or device related safety events within 7 days
of the procedure and a decrease in the rate of pericardial
effusions in the CAP Registry compared to the PRO-
TECT AF group (21). The authors concluded that there
is significant improvement in the safety of the device
with operator experience (21).
The confirmatory trial to evaluate improved safety and
efficacy were further addressed after the Aspirin and
Plavix (ASAP) feasibility study in the PREVAIL trial (22,
23). The prospective randomized clinical trial rando-
mized 407 patients from 41 participating US centers (23).
The main differences between PROTECT-AF and PRE-
VAIL were the exclusion of patients taking clopidogrel or
who had taken clopidogrel within 7 days of enrollment
and to include patients with a CHADS2 score ] 2o r
CHADS2 score1 (in patients not eligible for aspirin
therapy alone) (23). The first primary endpoint was the
occurrence of death, ischemic stroke, systemic embolism
and procedure or device-related complications requiring
cardiovascular or endovascular intervention within 7 days
post-randomization (23). Other endpoints included the
comparison of composite stroke, systemic embolism, and
cardiovascular/unexplained deaths at 18 months and
comparison of ischemic stroke or systemic embolism
occurring more than 7 days post-randomization also at
18 months (23). The preliminary data from the study
showed that the first endpoint of the occurrence of death,
ischemic stroke, systemic embolism and procedure or
device related complications requiring major cardiovas-
cular or endovascular intervention pre-specified criterion
were met and that there was improved procedural
implant success, decreased composite vascular complica-
tions, decreased procedural stroke rates, decreased per-
forations requiring surgical repair, and little difference in
outcome of new versus experienced operators (23). The
second endpoint through 18 months for composite
stroke, systemic embolism, and cardiovascular/unex-
plained death showed that the warfarin group had lower
than expected event rates though pre-specified non-
inferiority criterion was not met (23). The third endpoint
through 18 months for comparison of ischemic stroke or
systemic embolism occurring more than 7 days post-
randomization met pre-specified non-inferiority criterion
(23). Although promising, no conclusions could be made
until further completion of the study (23).
LARIAT device and accessories
Percutaneous LAA closure and exclusion using the
LARIAT device is a novel procedure that utilizes a pre-
tied suture to ligate the LAA (Fig. 4) (7).
Fig. 2. Amplatzer Cardiac Plug (27).
Fig. 3. WATCHMAN Device (28).
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study including 89 patients underwent LAA ligation
with a 1-year closure follow-up verified by TEE (24).
Of the 89 patients, 85 had successful LAA ligation
with 81 patients achieving immediate LAA closure (24).
Three of the 85 patients had B2 mm residual LAA
leak and one with B3 mm residual LAA leak demon-
strated by TEE (24). Complications included three
access-related (two pericardial and one trans-septal),
two with severe pericarditis post-operatively, one late
pericardial effusion, two unexplained sudden deaths, and
two late strokes thought to be non-embolic (24). Authors
of this study concluded that LAA closure using the
LARIAT device can be performed effectively with low
rates of complications and peri-procedural adverse events
(24).
Technical limitations of the procedure include: achiev-
ing pericardial access, device limitation with regards to
size, morphology, and appendage orientation. Potential
complications of PLACE are pericardial effusions, peri-
carditis, procedure-related chest pain, incomplete ligature
of the LAA, right ventricular puncture, LAA puncture,
and potential disruption of the epicardial vessels (25).
Although the FDA for stroke prevention does not
currently approve the device, ongoing prospective clinical
trials are currently in progress including the Close
Chested Epicardial Ligation of The Left Atrial Appen-
dage in Atrial Fibrillation (EAGLE) registry study. Table
1 compares and contrasts the different devices that were
discussed above.
Conclusion
Little is known about the alternative approaches to
the management of non-valvular AF in patients who
have intolerance to OAC. The ACP, WATCHMAN, and
LARIAT device show promising results; however, further
trials are needed to elucidate safety and efficacy for long-
term stroke prophylaxis. These devices may provide an
alternative to patients who remain intolerant to OAC,
are at high risk of bleeding, and to patients who wish
to remain off OAC altogether. By doing so, this will give
internists more options to provide stroke reduction
tailored to each individual patient. Although promising,
more randomized clinical trials are needed to establish
long-term safety and efficacy before a shift in AF
management can be ultimately made.
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